Search
DOTMP HO-166
go.drugbank.com/drugs/DB05380ExperimentalDOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to...
OXI-4503
go.drugbank.com/drugs/DB05143Investigationaldemonstrates that OXI-4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor infiltrates, to an orthoquinone chemical species that has … Preclinical studies have demonstrated that OXI-4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination
AMZ002
go.drugbank.com/drugs/DB17017InvestigationalAMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Phosphonoacetic Acid
go.drugbank.com/drugs/DB02823ExperimentalA simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. [PubChem]
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for...
Nifurizone
go.drugbank.com/drugs/DB19694ExperimentalNifurizone has a monoisotopic molecular weight of 307.09 Da.
Nifurethazone
go.drugbank.com/drugs/DB20112ExperimentalNifurethazone has a monoisotopic molecular weight of 269.11 Da.
Onametostat
go.drugbank.com/drugs/DB21480InvestigationalOnametostat has a monoisotopic molecular weight of 482.11 Da.
Gamcemetinib
go.drugbank.com/drugs/DB21624InvestigationalGamcemetinib has a monoisotopic molecular weight of 469.1 Da.
Vintafolide
go.drugbank.com/drugs/DB05168InvestigationalVintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.